Logo
5 Amino 1MQ 50mg (60 Capsules)

5 Amino 1MQ 50mg (60 Capsules)

Misc (Generics)

Research compound / peptide capsules
  • Marketed by multiple vendors as a research Only NNMT inhibitor compound, not evaluated or approved by the MHRA, FDA or other medicines regulators for therapeutic use.
  • Some suppliers state that batches are manufactured in GMP Compliant facilities and are third Party tested (e.g. COA, HPLC, MS) to confirm identity and purity for research purposes; these assurances relate to research quality rather than regulatory approval as a drug.
  • Typically sold with disclaimers that products are for laboratory research, development and in vitro use only, and not intended to diagnose, treat, cure or prevent any disease.
NNMT inhibitor small-molecule research capsule

Description

5-Amino-1MQ 50mg (60 Capsules) is a research-grade preparation of 5-amino-1-methylquinolinium, a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is an enzyme implicated in nicotinamide and NAD+ metabolism and has been linked in preclinical studies to adiposity, energy expenditure, insulin resistance and related metabolic pathways. Each capsule is reported to contain 50 mg of 5-Amino-1MQ, supplied in a bottle of 60 capsules. The product is marketed for laboratory and in vitro research focused on NNMT inhibition, cellular energy metabolism and metabolic disease models, and is not approved as a medicine or dietary supplement. No human dosing, safety or efficacy has been established, and reputable suppliers emphasise that it is intended for research use only and not for human or veterinary consumption.

Bnefits

  • Provides a convenient encapsulated form of 5-Amino-1MQ for use as a research tool in NNMT-related studies
  • Enables investigation of nicotinamide N-methyltransferase (NNMT) inhibition and its downstream effects on NAD+ metabolism and cellular energy pathways in experimental systems
  • Useful for exploring preclinical models of obesity, adiposity, insulin resistance and metabolic syndrome where NNMT activity is implicated
  • Supports mechanistic research into how NNMT inhibition may influence mitochondrial function, fatty acid oxidation and energy expenditure in cells and animal models
  • Available from multiple research suppliers with third-party analytical testing (e.g. COA, HPLC, MS) to confirm identity and purity for laboratory work
  • Capsule presentation simplifies handling and aliquoting for in vitro and preclinical experimental designs compared with bulk powders

Indications

  • In vitro and ex vivo research on NNMT biology and nicotinamide/NAD+ metabolism
  • Preclinical experimental models investigating obesity, adiposity and energy expenditure pathways
  • Laboratory studies of insulin resistance, glucose homeostasis and related metabolic disorders in cell and animal models
  • Mechanistic research into mitochondrial function, oxidative metabolism and sirtuin (e.g. SIRT1) signalling in relation to NNMT activity
  • Exploratory work on the role of NNMT in cellular ageing, inflammation and cardiometabolic risk, limited to non-human research settings
  • Use as a small-molecule probe compound in biochemical, pharmacological and molecular biology assays involving NNMT

Composition

  • Active compound: 5-Amino-1MQ (5-amino-1-methylquinolinium or 5-amino-1-methylquinolinium iodide; small-molecule NNMT inhibitor)
  • Per-capsule content: 50 mg 5-Amino-1MQ (as stated by multiple capsule suppliers for this strength)
  • Bottle contents: 60 capsules per container (total nominal active content 3,000 mg 5-Amino-1MQ)
  • Molecular formula (free base): C10H11N2
  • Molecular weight (free base): approximately 159.21 g/mol
  • CAS number (for 5-amino-1-methylquinolinium compounds used in NNMT research): 42464-96-0
  • Common synonyms: 5-amino-1-methylquinolinium; 5-amino-1MQ; 5A-1-molecule
  • Excipients/fillers: not specified by the seller; typical capsule excipients may include inert carriers such as cellulose or similar, but exact composition is not disclosed and may vary by manufacturer

Formulation

  • Oral hard capsule formulation containing 50 mg of 5-Amino-1MQ as the sole declared active ingredient
  • Capsules supplied in plastic or similar research-grade containers, intended for ease of handling in laboratory environments
  • Research-grade NNMT inhibitor with typical advertised purity of ≥99% and third-party analytical verification (e.g. HPLC, MS, COA) from several suppliers
  • Formulated and marketed specifically for research use (e.g. in vitro or preclinical models), not as a licensed medicinal product or dietary supplement
  • Solid, non-sterile capsule dosage form; not suitable for parenteral use and not produced under medicinal product marketing authorisation

Packaging

  • One bottle containing 60 capsules, each capsule nominally 50 mg of 5-Amino-1MQ
  • Container type commonly described by research suppliers as a plastic bottle or plastic laboratory container with a secure screw cap
  • Label information typically includes product name (5-Amino-1MQ 50mg), capsule count (60), research-only disclaimer (e.g. "for research use only", "not for human consumption"), lot or batch number, and expiry or best-before date
  • Shipped as a non-sterile, solid oral capsule product suitable for storage in standard laboratory chemical storage conditions

Usage

  • This product is sold and described by reputable vendors as a research compound intended for in vitro or preclinical experimental use only.
  • It is not approved as a medicine, dietary supplement or cosmetic, and is not intended for human or veterinary consumption or self-administration in any form.
  • No therapeutic dosage, route of administration, treatment schedule or clinical protocol is established or provided for human use.
  • Researchers handling 5-Amino-1MQ capsules should follow their institution’s laboratory safety procedures for small-molecule research chemicals, including appropriate personal protective equipment (PPE), handling, and disposal.
  • Experimental design (e.g. dissolution of capsule contents, preparation of stock solutions, concentration ranges in vitro) should be defined by qualified researchers based on the scientific literature, local regulations and internal risk assessments.
  • Any off-label or non-research use is strongly discouraged and falls outside the intent of the product as marketed by research chemical suppliers.

Contraindications

  • Not for human consumption or use as a drug, supplement or cosmetic product under any circumstances.
  • Not for veterinary use or administration to animals outside controlled, ethically approved research protocols.
  • Handling is contraindicated for individuals with known hypersensitivity to quinoline-derived compounds or any component of the capsule formulation, from an occupational exposure standpoint.
  • Use in any setting that does not comply with applicable regulations for handling experimental chemicals (e.g. GLP/GMP labs, institutional safety policies) is inappropriate.
  • Inappropriate for use in self-experimentation, unsupervised administration, or any context lacking ethical and regulatory oversight.

Adverse Effects

  • No formal human safety, tolerability or adverse-effect profile has been established for 5-Amino-1MQ, as it is not an approved medicinal product.
  • Any discussion of potential toxicology is based on preclinical data in cells and animal models and cannot be directly extrapolated to humans.
  • Potential risks in humans, if misused, could include off-target pharmacological effects, unknown toxicity to organs involved in NAD+ metabolism (e.g. liver, kidney, adipose tissue), and unforeseen interactions with other compounds or disease states.
  • Laboratory personnel may experience irritation or sensitisation from accidental contact or inhalation of dust if capsules are opened and contents handled without appropriate PPE.
  • Because comprehensive toxicology and clinical testing in humans are lacking, all adverse-effect risks for non-research use must be considered unknown and potentially significant.

Storage Conditions

  • Store in a cool, dry place at stable room temperature as typically recommended for solid research chemicals (for example, around 15–25 °C), unless the specific supplier label states otherwise.
  • Keep the container tightly closed when not in use to protect capsules from moisture, air and contamination.
  • Protect from direct sunlight, excessive heat and sources of ignition.
  • Do not freeze, and avoid large temperature fluctuations that could affect compound stability.
  • Store out of reach of unauthorised personnel, children and pets, in accordance with institutional chemical storage policies.
  • Dispose of expired or unused material in line with local regulations for laboratory chemical waste.

Duration

Not applicable \u2013 5-Amino-1MQ capsules are marketed as research compounds only, with no approved therapeutic regimen, treatment duration or clinical protocol established for human or veterinary use.

Onset

Not applicable in a clinical sense \u2013 while preclinical studies in cells and animal models report metabolic effects associated with NNMT inhibition, there are no authorised human indications or evidence-based onset-of-effect timelines for therapeutic use.

Browse more Research compound / peptide capsules

Top Treatments

Top Cities in the UK